Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma
Conclusions
Nab-paclitaxel and EBRT was well-tolerated at doses below 100 mg/m2. The MTD and recommended phase II study dose for nab-paclitaxel with EBRT is 75 mg/m2 in this disease.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | External Beam Therapy | Gastroenterology | Pancreas | Pancreatic Cancer | Study | Toxicology